C. Jomphe

Population PK Modeling of Ziftomenib and its Metabolites in Healthy Subjects and in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amitava Mitra, Xiao-Yan Yang, Roberto Ortiz, C. Jomphe +2 more

2026Population PK Modeling of Ziftomenib and its Metabolites in Healthy Subjects and in Patients with Relapsed or Refractory Acute Myeloid Leukemia0 citations Open access

Semantic Scholar

C. Jomphe

Most-cited papers

The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-κB in interleukin-1β-stimulated chondrocytes

Ammonia control in children with urea cycle disorders (UCDs); Phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate

Blocking spinal CCR2 with AZ889 reversed hyperalgesia in a model of neuropathic pain

Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes.

Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons

Use of TH-EGFP transgenic mice as a source of identified dopaminergic neurons for physiological studies in postnatal cell culture.

Expression of D2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function.

Population Pharmacokinetic–Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration

The 21-aminosteroid U74389G prevents the down-regulation and decrease in activity of CYP1A1, 1A2 and 3A6 induced by an inflammatory reaction.

Population pharmacokinetics and exposure–response relationships of maribavir in transplant recipients with cytomegalovirus infection

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema

Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria

Population Pharmacokinetic Modeling of Subcutaneous Plozasiran in Healthy Volunteers and Patients with Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia, and Mixed Hyperlipidemia

Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome

Population Pharmacokinetics and Exposure‐Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetics and Exposure–Response Relationships of Maribavir in Transplant Recipients With First Episode or Refractory Cytomegalovirus

Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long‐Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin

Population Pharmacokinetics and Exposure–Response Relationships of Maribavir in Transplant Recipients with Cytomegalovirus Infections

AML-771: Exposure-Response Analysis of Ziftomenib Combined With Venetoclax/Azacitidine or Cytarabine/Daunorubicin in Newly Diagnosed and Relapsed/Refractory NPM1-M or KMT2A-R Acute Myeloid Leukemia

Population PK Modeling of Ziftomenib and its Metabolites in Healthy Subjects and in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Exposure-Response Analysis of Ziftomenib in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Population PK and exposure-response (ER) analyses to support dosing of teduglutide in infant patients with short bowel syndrome (SBS)

Régulation de la fonction du récepteur dopaminergique D2 dans les neurones dopaminergiques

K-PD model of Plozasiran in Patients with Severe Hypertriglyceridemia